Analisis Biaya Kemoterapi Pasien Kanker Payudara Dan Kanker Serviks Di RSUD Ulin Banjarmasin

N Aisyah, A Syarifuddin, P Amami… - Jurnal Insan Farmasi …, 2020 - e-jurnal.stikes-isfi.ac.id
Indonesia yang memerlukan tindakan/intervensi kesehatan masyarakat. Pembiayaan
kanker pada Jamkesmas tahun 2012, menempati urutan ke-2 sebanyak Rp. 144, 7 M …

The Suitability of Direct Medical Costs with INA-CBG'S Claims of Outpatient Breast Cancer in Class A and B Hospitals

DA Nugraheni, FA Hafi'ah… - Jurnal Ilmu …, 2024 - ejournal.fkm.unsri.ac.id
BPJS Kesehatan noted that cancer financing claims reached IDR 3.5 trillion, ranking second
after heart disease. This study aimed to determine the difference in direct medical costs with …

Cost-Consequence Analysis of Levofloxacin Compared to Ceftriaxone in Community-Acquired Pneumonia of Adult Inpatients at X Hospital Surakarta

R Rahardjoputro, A Wardhana Amrullah, J Santoso… - 2024 - repository.unar.ac.id
Background: Community-acquired pneumonia is still a significant cost-burden disease in
healthcare facilities. Pharmacoeconomic analysis using the cost-consequence analysis …

POST-CHEMOTHERAPY TREATMENT IN NATIONAL HEALTH INSURANCE BREAST CANCER PATIENTS AT YOGYAKARTA CITY HOSPITAL

DP Anggraeni, F Yuliastuti - Medical Sains: Jurnal Ilmiah …, 2024 - ojs.ummada.ac.id
Breast cancer accounts for approximately 16.6% of 396,914 cases of cancer and is one of
the most fatal and common diseases among women. Treatment of breast cancer mostly has …

Analysis of Differences Between Hospital Rates and INA-CBG's Claim of Sectio Caesarea

A Hayati, SC Budi, IA Dani - Procedia of Engineering and Life …, 2024 - pels.umsida.ac.id
Hospitals as advanced referral facilities have an important role in implementing the National
Health Insurance (JKN) programme. For payment of advanced health services for JKN …

[PDF][PDF] THE SUITABILITY OF DIRECT MEDICAL COSTS WITH INA-CBG'S CLAIMS OF OUTPATIENT BREAST CANCER IN CLASS A AND B HOSPITALS

A Tetuko, TR Indarti, G Mayasari - pdfs.semanticscholar.org
BPJS Kesehatan noted that cancer financing claims reached IDR 3.5 trillion, ranking second
after heart disease. This study aimed to determine the difference in direct medical costs with …

COMPARATIVE OF REAL COST AGAINST THE PRICE OF INA-CBG'S BREAST CANCER AND ITS AFFECTING FACTORS IN JKN PROGRAM ERA

A Santoso, IH Sulistyaningrum… - … Farmasi Sains dan …, 2020 - journal.unimma.ac.id
This study aims to determine differences in real cost and INA CBG's rate and to find out the
factors that influence the difference between the real cost and INA CBG's rate in patient with …

[PDF][PDF] Bioassay-guided Fractionation, LC/MS Analysis and In Vitro Cytotoxic Activity of Eriocaulon cinereum R. Br on T47D Breast Cancer Cells

M Taib, AP Ramadani - researchgate.net
In this study, we examined the cytotoxic activity of Eriocaulon cinereum R. Br. against breast
cancer T47D cells and normal Vero cells. The plant material of E. cinereum was extracted …

[PDF][PDF] ANALISIS EFEKTIVITAS BIAYA KEMOTERAPI PADA PASIEN KANKER PAYUDARA DI RSPAD GATOT SOEBROTO JAKARTA

J Pontoan - repository.istn.ac.id
Breast cancer is a disease of malignant neoplasm which is an abnormal growth of tissue that
is different from the surrounding tissue. Various used of chemotherapy in the process of …

[PDF][PDF] PERBANDINGAN BIAYA RIIL DENGAN TARIF INA-CBG'S PENYAKIT KANKER PAYUDARA PADA ERA JAMINAN KESEHATAN NASIONAL COMPARATIVE …

ASIH Sulistyaningrum, A Rosyid, EB Cahyono… - academia.edu
Studi ini bertujuan untuk mengetahui perbedaan biaya riil rumah sakit dengan tarif
INACBG's dan untuk mengetahui faktor-faktor yang mempengaruhi perbedaan biaya riil …